Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by PTBaileyon May 03, 2022 11:00am
169 Views
Post# 34651072

RE:Phase one

RE:Phase one
polo22 wrote: Mr. Bailey....do you know if  phase one is ongoing 


From another poster on FB site...

"I emailed Bob and he responded that phase 1 is 80% funded and they will be doing a investor debenture shortly and getting the rest from an institution investor in the next 3-4 weeks which will finish the Phase 1 and the Phase 2 a got the PAH. I emailed him as the share price has tanked 50% in the last week and he indicated the 2 shorters are knocking it down and there is nothing we can do to counter until we get the institutional money and phase 1 completed.
I spoke with Bob a week ago on where they are at with phase 1 and the medication was just arriving so it should have started or very soon to be started. Thought I would share as we are in the dark on where it’s at."
<< Previous
Bullboard Posts
Next >>